Mikyung Yu

Dr. Mikyung Yu is an instructor in the Farokhzad Lab at Harvard Medical School (HMS) and Brigham and Women’s Hospital (BWH). She received her Ph.D. in Life Sciences from Gwangju Institute of Science and Technology (GIST) for her research work on nanomedicine and biomaterials in South Korea (2010). She then served as postdoctoral fellow in the School of Life Sciences, GIST (2010-2012) and in the Laboratory of Nanomedicine and Biomaterials at HMS (2013-2015). She currently leads several projects aimed at the development of novel nanomedicines and biomarkers for atherosclerotic vascular diseases.

Email Google Scholar LinkedIn

Morteza Mahmoudi

Dr. Morteza Mahmoudi is an instructor in the Farokhzad Lab at Harvard Medical School (HMS) and Brigham and Women’s Hospital (BWH). He is also the director of the NanoBio Interaction Laboratory ( at Tehran University of Medical Sciences. He received his Ph.D. working the development of ultra-safe superparamagnetic iron oxide nanoparticles for various biomedical applications at Sharif University of Technology in 2009. He then attended several universities (e.g., University College Dublin, École Polytechnique Fédérale de Lausanne, University of Illinois Urbana-Champaign, and Stanford School of Medicine) as a postdoc/visiting-scholar/visiting-professor. Dr. Mahmoudi’s diverse engineering and medical training uniquely prepared him to perform multi-disciplinary research at the convergence of physics, chemistry, materials, biology, and medicine, which he now applies to the development of “smart” nanobio-materials for cancer therapy with predictable/controllable protein corona structure.

Email Google Scholar LinkedIn

Xiaoding Xu

Dr. Xu received his Ph.D. in polymer chemistry in 2011 from Wuhan University. He is an instructor at Brigham and Women’s Hospital, Harvard Medical School. His research interests include biomaterials, nanotechnology and drug/gene delivery. Dr. Xu is currently developing stimuli-responsive nanomaterials for targeted and deeply penetrated delivery of biomacromolecules (e.g. siRNA) and small molecular drugs for cancer therapy.

Email Google Scholar LinkedIn